HALO Halozyme Therapeutics, Inc.
XNAS
102.14
−0.82%
Pre-market
Stock quote, options chain, IV rank, technicals, AI analysis, and institutional ownership. Iron condor setups Expected move IV rank history Fibonacci levels Insider trading
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
HALO
$102.14
▼ -0.82%
What changed
Recent filings, trades and movesKey stats
$102.98
Pre-market
$102.14
-0.82%
- 52-Week Range
- $61.23 – $134.00
- YTD
- +46.47%
- IV Rank (30D)
- 48.61
- Straddle Price
- $10.97
- P/C Vol Ratio
- 2.19
- Market Cap
- $11.7B
- Open
- $101.92
- Day Range
- $101.38 – $105.45
- Volume
- 2,251,954
- Prev Close
- $102.92
Fair Value
+50.0% vs price
A blended fair-value estimate combining up to six valuation methods. Each method is weighted by how well it fits the company — DCF down-weights for unprofitable names; DDM only fires for steady dividend payers; comparables down-weight when peer multiples disagree.
- DCF (quality-aware) — projects free cash flow with a horizon that scales to business quality. True compounders (quality 6/6) get 10 years explicit + 10 years fade before terminal; cyclical/struggling names (quality 0-1) get a 5-year terminal cliff. Quality is scored from ROE, gross margin, growth, FCF margin, debt load, and FCF consistency — the same factors that drive market premium for compounders.
- Market-Implied Growth (in Model Inputs) — reverse-DCF that answers "what growth rate is the market pricing in?". Lets you sanity-check the deviation: if implied growth is plausible for the business, the model's bearish flag may be wrong; if implausible, the market may be over-extrapolating.
- DDM (Gordon Growth Dividend Model) — values the stream of future dividends. Only used when trailing yield ≥ 2% and dividend payments are stable — below that the dividend is a token payout and Gordon (which values only the dividend stream) systematically underprices growth names, so those route to DCF + comparables + market anchor instead.
- P/E, EV/EBITDA, P/B, P/S — applies the peer-group median multiple to this company's per-share metric. Peers come from the same set as the "Related symbols" card. Earnings/sales metrics are forward-tilted by the company's recent revenue growth (capped at 25%) so they're comparable to peers' growth-embedded multiples — mimics how analysts use NTM rather than TTM. Per-multiple weights are biased by company quality (e.g. P/B down-weighted for asset-light tech).
- Market Anchor (SMA50) — the 50-day moving average, weighted by recent trading-range stability (tighter Bollinger bands → higher weight). Captures information fundamentals miss (forward consensus, sentiment, supply/demand) — but only when recent trading is steady enough that the market has converged on a view. During wild breakouts or breakdowns the anchor's weight collapses.
- Options Expected (B-L 30d) — the risk-neutral expected stock price at 30-day options expiration, derived from the full implied-volatility surface via Breeden-Litzenberger (second derivative of call price wrt strike → implied PDF, then E[S_T]). Forward-looking, captures all options-implied information (smile, skew, term structure) in one number. Weighted by chain liquidity. SP500-only at present (pre-computed daily). Backtest evidence: adds modest alpha across most bucket × holding combos.
- Blended value — weighted average. Confidence reflects how many methods fired and how tight peer dispersion is.
- Deviation pill — green when blended FV ≥ 10% above current price (undervalued); red when ≥ 10% below; grey otherwise.
| 10-yr Treasury (rf) | 4.86% |
| Beta vs SPY | 0.82 |
| Cost of Equity (CAPM) | 8.98% (VRP-adj) |
| WACC | 8.44% |
| Volatility Risk Premium | +9.5pp (IV − HV30) |
| Effective Tax Rate | 29.1% |
| Rev. Growth (YoY, DCF input) | +30.0% |
| DCF Horizon | 12 years explicit + fade |
| Forward Tilt (NTM/TTM) | ×1.10 (applied to P/E, EV/EBITDA, P/S) |
| Free Cash Flow (TTM) | $0.8B |
| Return on Equity (TTM) | 288.1% |
| Book / Price | 1.1% |
| Gross Margin (TTM) | 82.4% |
| FCF Margin (TTM) | 48.5% |
| Debt / Equity | 13.50 |
| Quality Score | 5/6 — high quality (12y DCF) |
| Market-Implied Growth | +2.9% (reverse-DCF on current price) |
| SMA 50 | $115.07 (Market Anchor value) |
| SMA 20 / Bollinger Mid | $122.55 |
| Bollinger Width / SMA20 | 29.1% (drives anchor stability) |
| Net Debt | $1.8B |
| Market Cap | $12B |
Peers used for multiples: AMGN, BIIB, EXEL, GILD, NBIX, REGN, UTHR, VRTX
Blended Fair Value
$270.26
Deviation
+50.0%
| Method | Implied Price | Weight | Detail |
|---|---|---|---|
| DCF | $660.23 | 30% | |
| DDM (Gordon) | n/a | 0% | |
| Peer P/E | $91.80 | 13% | median 24.3× · 7 peers |
| Peer EV/EBITDA | $149.80 | 13% | median 17.3× · 8 peers |
| Peer P/B | $6.57 | 3% | median 5.5× · 8 peers |
| Peer P/S | $100.02 | 9% | median 6.6× · 8 peers |
| Market Anchor (SMA50) | $115.07 | 3% | stability 5% (BB-width) |
| Options Expected (B-L 30d) | $103.99 | 30% | 22 strikes · skew +0.52 |
As of 2026-11-11 · updated
Related
About
- Industry (SIC)
- BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) (2836) · industry map
- Exchange
- XNAS
- Market Cap
- $11.7B
- Employees
- 423
- List Date
- 2004-03-12
- CIK
- 0001159036
- Last Earnings
- Nov 5 after close · −15.7% vs ±10.7% expected
- Next Earnings
- ~Feb 16, 2027 (estimated)
- Headquarters
- San Diego, CA
- Homepage
- https://www.halozyme.com
Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. ENHANZE drug delivery technology was introduced with the proprietary enzyme rHuPH20, to facilitate the subcutaneous delivery of injected drugs and fluids, with the goal of improving the patient exp…
Summary
—
composite
—
No summary data available for this symbol yet.
Each spoke is this symbol's rank within its sector (0–100; the dotted ring marks the sector median at 50). Higher is more constructive for a long. One spoke — News sentiment — is an absolute reading, not a sector rank. Grayed spokes have no data. A fuller shape is a summary, not a recommendation.
Chart
Seasonality
| Month | '21 | '22 | '23 | '24 | '25 | '26 | Avg |
|---|---|---|---|---|---|---|---|
| Jan | 12.21% | -15.71% | -6.09% | -9.47% | 17.98% | 1.99% | 0.15% |
| Feb | -5.06% | 0.94% | -8.01% | 16.20% | 5.10% | -6.61% | 0.43% |
| Mar | -10.29% | 11.93% | -19.80% | -1.05% | 10.09% | -7.47% | -2.77% |
| Apr | 17.72% | -4.11% | -17.06% | -7.79% | -0.73% | -2.66% | -2.44% |
| May | -15.97% | 12.56% | -0.61% | 12.70% | -6.60% | 4.03% | 1.02% |
| Jun | 9.74% | -3.08% | 11.02% | 16.23% | -6.51% | 14.87% | 7.04% |
| Jul | -10.85% | 9.94% | 16.49% | 6.23% | 13.32% | 7.32% | 7.08% |
| Aug | 3.55% | -16.07% | 0.66% | 15.99% | 23.94% | 29.44% | 9.59% |
| Sep | -3.17% | -2.56% | -10.79% | -6.50% | 0.00% | 2.49% | -3.42% |
| Oct | -6.58% | 19.35% | -10.14% | -10.72% | -13.01% | 22.41% | 0.22% |
| Nov | -15.76% | 18.60% | 15.22% | -15.66% | 7.85% | -20.14%* | -1.65% |
| Dec | 24.99% | -0.87% | -6.88% | -1.61% | -1.17% | -- | 2.89% |
| Total | -8.78% | 25.68% | -36.05% | 7.31% | 54.09% | 42.68% | 14.16% |
Technical Indicators
Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.
Trend Indicators
- SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
- EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
- MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
- ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
- +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
Momentum Oscillators
- RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
- Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
- Williams %R — inverted scale: <−80 oversold, >−20 overbought.
Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.
Volume & Volatility
- Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
- OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
- Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
- ATR / True Range — average daily $ move; sizing and stop-loss reference.
- HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.
Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →
Trend Indicators
SMA 20: $122.55
SMA 50: $115.07
SMA 200: $84.99
Current: $102.98
EMA 12: $117.30
EMA 26: $118.21
MACD: -0.9123 | Signal: -3.5606
BULLISH
ADX (14): 38.06
TREND
+DI: 15.12
−DI: 40.19
Momentum Oscillators
RSI (14): 28.81
OVERSOLD
Stoch %K: 5.04
Stoch %D: 13.67
Williams %R: -94.11
Volume & Volatility
BB Upper: $140.37
BB Lower: $104.74
OVERSOLD
OBV: 48,188,650
Vol SMA 20: 2,477,040
Vol ROC: 32.20%
ATR: $4.86
True Range: $4.07
HV 20: 72.3%
HV 30: 60.5%
HV 60: 46.1%
Data Summary
Data Points: 500
Last Updated:
Date Range: 2024-11-12T00:00:00 – 2026-11-10T00:00:00
AI Analysis
Written before HALO’s Nov 5 earnings report, so it doesn’t reflect the results.
LLM Stock Analysis Report
Executive Summary
Overall assessment: NEUTRAL (Confidence level: 6/10)
Key drivers:
- Strong technical signals with bullish MACD crossover
- Positive news sentiment from recent headlines
- Low volatility indicating stability
Primary risks:
- Potential for pullback as price approaches upper Bollinger Band
- Earnings season uncertainty may impact stock performance
Investment thesis: Halozyme Therapeutics (HALO) is a biotech company with strong fundamentals and technical signals. Recent news has been positive, and the options market expects a moderate move by expiration.
Recent news sentiment impact: Positive news headlines have contributed to the current price level, but overall sentiment remains neutral.
Technical Analysis
Trend direction:
- Short-term (1-4 weeks): Bullish
- Medium-term (1-3 months): Neutral
- Long-term (3-12 months): Bullish
Support/resistance levels: Key price levels include SMA 20 ($66.54), SMA 50 ($65.75), and Bollinger Band upper level ($71.19).
Momentum signals:
- RSI interpretation: Neutral (54.34)
- MACD signal: Bullish (0.71 / Signal: 0.20 / Histogram: 0.51)
- Bollinger Bands position: Squeeze, but price is approaching the upper band
Volume analysis:
- Volume SMA 20: 1770358.10
- On-Balance Volume (OBV): 37823363.64
- Volume Rate of Change: -29.83%
News & Sentiment Analysis
Recent headlines summary:
- Neutral news from recent headlines, with no significant market-moving events
Sentiment assessment:
- Positive sentiment from recent headlines (4/5) is offset by neutral overall sentiment (3/5)
Catalyst identification:
- Upcoming earnings report on May 12, 2026, may impact stock performance
- Participation in the Stifel 2026 Virtual CNS Forum on March 26, 2026
Market narrative: News sentiment aligns with the current price level and technical signals.
Risk & Volatility Assessment
Beta interpretation:
- Beta of 0.61 indicates low volatility relative to the market (SPY)
Volatility regime:
- Current volatility is lower than historical levels
Options market signals:
- IV rank: Medium
- Put/call ratios: 0.29 (Bullish sentiment)
- Unusual activity: None
Downside protection:
- Support level at SMA 20 ($66.54) and Bollinger Band middle level ($66.54)
Market Context & Positioning
Sector performance:
- Halozyme Therapeutics is part of the biotech sector, which has been performing well recently
Institutional activity:
- Volume patterns suggest institutional interest, but no significant buying or selling pressure
Correlation analysis:
- Correlation with SPY: 0.25 (Low)
Relative valuation:
- Position within trading range, with potential for breakout above the upper Bollinger Band
Key Levels & Action Items
Critical price levels:
- SMA 20 ($66.54)
- SMA 50 ($65.75)
- Upper Bollinger Band ($71.19)
Breakout/breakdown levels:
- SMA 20 ($66.54) - potential support
- SMA 50 ($65.75) - potential support
- Upper Bollinger Band ($71.19) - potential resistance
Time-sensitive catalysts:
- Earnings report on May 12, 2026
Risk management:
- Stop-loss levels: Below SMA 20 ($66.54)
- Position sizing considerations: Consider reducing position size ahead of earnings report
Generated
News
All HALO news →
Merck patent setbacks in the U.S. cloud an otherwise strong quarter for royalties.
Showing 1–10 of 12
Page 1 of 2
Earnings History
14 of 24 under expected move
Avg Expected Move
7.63%
Avg Actual Move
6.51%
| Earnings Date | Timing | Expected Move | Actual Move | Ratio | Outcome |
|---|---|---|---|---|---|
| 2021-01-11 | After-Close | 8.42% | 1.36% | 0.16x | Within |
| 2021-05-10 | After-Close | 9.11% | 7.42% | 0.81x | Within |
| 2021-08-09 | After-Close | 8.16% | 1.98% | 0.24x | Within |
| 2021-11-02 | After-Close | 8.94% | 1.42% | 0.16x | Within |
| 2022-01-10 | After-Close | 7.78% | 1.67% | 0.21x | Within |
| 2022-05-10 | After-Close | 8.77% | 0.99% | 0.11x | Within |
| 2022-08-09 | After-Close | 6.23% | 1.78% | 0.29x | Within |
| 2022-11-08 | After-Close | 7.86% | 8.47% | 1.08x | Exceeded |
| 2023-01-10 | After-Close | 2.51% | 9.23% | 3.68x | Exceeded |
| 2023-05-09 | After-Close | 6.54% | 12.79% | 1.96x | Exceeded |
| 2023-08-08 | After-Close | 7.69% | 1.57% | 0.20x | Within |
| 2023-11-06 | After-Close | 8.74% | 10.04% | 1.15x | Exceeded |
| 2024-01-17 | After-Close | 4.22% | 3.08% | 0.73x | Within |
| 2024-05-07 | After-Close | 7.40% | 1.94% | 0.26x | Within |
| 2024-08-06 | After-Close | 8.04% | 4.20% | 0.52x | Within |
| 2024-10-31 | After-Close | 9.94% | 13.01% | 1.31x | Exceeded |
| 2025-02-18 | After-Close | 6.91% | 0.22% | 0.03x | Within |
| 2025-05-06 | After-Close | 7.79% | 18.12% | 2.33x | Exceeded |
| 2025-08-05 | After-Close | 11.02% | 2.48% | 0.23x | Within |
| 2025-11-03 | After-Close | 8.50% | 2.79% | 0.33x | Within |
| 2026-02-17 | After-Close | 5.00% | 9.01% | 1.80x | Exceeded |
| 2026-05-11 | After-Close | 5.95% | 6.81% | 1.14x | Exceeded |
| 2026-08-06 | After-Close | 6.94% | 20.24% | 2.92x | Exceeded |
| 2026-11-05 | After-Close | 10.65% | 15.72% | 1.48x | Exceeded |
Earnings calendar: this week’s reports with expected vs actual moves →
HALO Options Activity & IV Rank
HALO IV rank history, 52-week IV rank and IV percentile →
Volatility Metrics
Current IV: 40.5%
7-DTE IV: 40.3%
Expected Move: $10.97
7-DTE Move: $5.78
Days to Exp: 38 (2026-12-18)
Options Flow · All expiries
Call Volume: 769
Put Volume: 1,685
P/C Volume: 2.191
BEARISH
Call OI: 16,649
Put OI: 5,610
P/C OI: 0.337
Total OI: 22,259
ATM Options Pricing
ATM Call: $4.62
ATM Put: $6.35
Call %: 4.5%
Put %: 6.2%
Chain Summary
Chain Volume: 2,454
Chain OI: 22,259
Last Updated: 11/10/2026
Spread Scanner
Each spread is ranked by a composite score built in three stages. Full documentation →
Stage 1 — Base Score
score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.
Calendars: the long leg is valued at the short leg’s expiration (Black-Scholes at its current IV) across the range of prices the short leg’s IV implies, giving the best-case profit (R/R = that over the debit) and P(profit).
Stage 2 — Skew Adjustment (±25% cap)
RR and BF (30-delta) from the persisted per-symbol skew snapshot — wing strikes picked by real greeks.delta, not a moneyness proxy. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.
Stage 3 — Technical Overlay (±50% cap, 5 groups)
Group 1 · Directional Bias (±0.25)
- RSI <40 bullish / >60 bearish
- MACD crossover + histogram trend
- Price vs SMA 50 & SMA 200
Group 2 · Momentum (±0.10)
- Stochastic %K <20 / >80
- Williams %R <−80 / >−20
Group 3 · Volatility (up to −0.25 / +0.15)
- Blended ATR + straddle expected-move penalty
- Bollinger Band signal (+ counter-trend penalty)
- BB width — vol contraction boost for ICs
Group 4 · IV Regime (±0.15)
- IV rank ≥ 75 → strong boost for credit spreads
- IV rank < 25 → penalty (selling cheap vol)
Group 5 · Liquidity (penalty up to −0.10)
- Min open interest across all legs
- OI < 100 → −0.10 · OI < 500 → −0.05
score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →
Scanning bull put, bear call, iron condor and calendar spreads…
Dealer Positioning
LOW γ vs HISTORY
Estimated net dealer gamma is at the 0th percentile of this name's own daily history, near the low end of its range. This describes current positioning; it is not a forecast or a trading signal.
Gamma percentile
0%
vs own history
GEX tilt
-0.28
OI-weighted, today
Vanna tilt
+0.12
δ-sensitivity to IV
Charm tilt
-0.02
δ-decay vs time
? What is this?
· 22 ATM contracts, 6k total OI
Net dealer gamma is an estimate of the aggregate gamma held by options market makers across this name's option chain, weighted by open interest. Dealer positions aren't public, so it uses a standard simplifying assumption: dealers are treated as long the calls and short the puts that are open. Actual dealer books can differ.
Gamma percentile ranks today's estimate against this name's own daily history, from 0% (the lowest reading on record) to 100% (the highest). Raw gamma scales with how much open interest a chain carries, so it isn't comparable across names; the percentile is. The badge marks the bottom 20% as low and the top 20% as high.
Tilts run from −1 to +1 and show how lopsided the estimated dealer exposure is. GEX tilt compares call gamma with put gamma. Vanna tilt describes how the hedge would shift if implied volatility changed, and charm tilt how it would shift with the passage of time.
This card describes estimated positioning and where it sits historically. It is not a forecast of price direction or volatility and not a trading signal. Market-wide view: Dealer positioning screener.
Skew (Wing IV − ATM IV)
DTE:
Wing Δ:
Wing vs ATM
IV(put wing) − IV(ATM), in vol pointsHow much the OTM put trades above (or below) the at-the-money strike. Measures the height of the put-side tail relative to ATM — i.e. how expensive crash insurance is on this name.
- Positive (typical) — wing IV > ATM IV. Standard equity put skew: portfolios bid up crash protection, so OTM puts trade richer than ATM.
- Near zero or negative (unusual) — wing IV ≤ ATM IV. Flat or inverted put side. Common when there's no fear demand, in tightly mean-reverting names, or right after an earnings catalyst clears.
- Percentile vs own 3-yr history: high = wings rich (good time to sell wing premium); low = wings cheap (good time to buy protection).
- Not directional — high or low wings don't predict up or down moves. It's a price tag on tail insurance, not a forecast.
Risk Reversal
IV(call wing) − IV(put wing), equal delta on each sideWhich side of the smile is the market paying up for? Measures the tilt of the surface — call skew vs put skew at matched deltas.
- Negative (typical) — puts richer than calls. Standard equity behavior: hedging demand makes puts carry a premium. Most large-caps sit in the −1 to −5 vol-point range.
- Strongly negative (< −5 pts) — heavy downside hedging, elevated fear, or an upcoming catalyst (earnings, FDA, macro event). Worth flagging.
- Positive — calls richer than puts. Unusual for equities; signals bullish momentum, short-squeeze positioning, or takeover/M&A speculation.
- Near zero — symmetric surface. Market sees roughly equal up/down risk. Rare for large-caps; more common in commodities and FX.
Reading them together
Wing-vs-ATM tells you how expensive the tails are. Risk Reversal tells you which side is favored. Combined:
- High wing percentile + deeply negative RR → strong put bid; stress or major event priced in. Owning protection costs a premium; selling put premium is dangerous.
- Low wing percentile + near-zero RR → complacency; insurance cheap and balanced. Good environment to add cheap downside hedges.
- Positive RR + elevated wings → call-side fear-of-missing-out; common in squeeze setups. Upside calls expensive, downside puts not bid.
14 DTE / 10d
—
—
pts
EXTREME
as of Nov 10 · No data
30 DTE / 10d
—
—
pts
EXTREME
as of Nov 10 · No data
Extreme reading.
Historically these have been contrarian — on the small set of observed earnings-day cases, large negative wing-vs-ATM gaps (calls pricing much richer than puts at the same delta) preceded sharp drops in the underlying within 1-12 days. Not financial advice and the dataset is small.
Percentile is the rank of today's reading within ~3 years of this symbol's own history. High percentile = wings are rich relative to history; not a directional signal. Skew is read off the chain in real time, not from CBOE SKEW.
Volatility Surface
Loading the implied volatility surface…
Volatility Smile
Loading the implied volatility smile…
IV Rank (7 DTE)33.2MediumNov 10
IV Rank (30 DTE)48.6MediumNov 10
Straddle Price (30 DTE)$10.97Nov 10
Beta Analysis
Risk Metrics
Beta: 0.5740
Alpha: 43.97%
Correlation: 0.1908
R-Squared: 3.6%
Stock Volatility: 41.1%
Market Volatility: 13.7%
Analysis Details
Benchmark: SPY
Data Points: 251
Period: 252 trading days
Data Points: 251
Period: 252 trading days
Interpretation:
Low volatility - stock moves less than market
Low volatility - stock moves less than market
Beta & Alpha Over Time
Notable investors who own HALO
6 of 37 tracked investors
| Investor | Value | Share of their portfolio | Rank | Q/Q shares | Source |
|---|---|---|---|---|---|
| Renaissance Technologies Hedge fund Jim Simons | $37.5M | #436 of 3138 | -34.5% | 13F | |
| Bridgewater Associates Hedge fund Ray Dalio | $36.3M | #113 of 997 | -9.4% | 13F | |
| Citadel Hedge fund Ken Griffin | $35.9M | #843 of 6285 | -72.7% | 13F | |
| Point72 Hedge fund Steve Cohen | $8.4M | #814 of 1945 | -86.3% | 13F | |
| Millennium Management Hedge fund Izzy Englander | $1.6M | #2702 of 3716 | -95.8% | 13F | |
| Rockefeller Capital Management Family office Rockefeller family | $635K | #1961 of 4729 | +6.4% | 13F |
Hedge funds, activists, holding companies and family offices we track, from their latest 13F (quarter-end value) and Form 4 filings in the last 3 years. Family offices · all institutions
HALO Institutional Ownership (13F)
Filings for 2026-06-30 · 382 already for 2026-09-30
? 13F Guide
Diluted shares outstanding: 122,581,250 (as of 2026-06-30)
Institutional managers with $100M+ AUM file Form 13F-HR quarterly, due 45 days after quarter end. Holdings are reported gross at quarter-end market value — they are a snapshot, not a real-time position.
- Shares — long equity positions in this name, aggregated across share classes.
- Calls / Puts — notional value of long call / put exposure where this ticker is the underlying.
- % of Float — holder's reported shares divided by the latest diluted shares outstanding. Sums above 100% indicate large custodian / prime broker positions where the same shares are reported by multiple filers.
- Custodian badge — filers with more than 5,000 holdings are typically broker-dealers / custodians reporting customer-held shares, not active managers.
Each filer is counted once at its latest 13F-HR filing. New filings are ingested on a weekly cadence.
11 filers$72.99M notional
| # | Filer | Notional Value | % of Total | Period |
|---|---|---|---|---|
| 1 | Susquehanna International Group, LLP Custodian | $29.66M | 40.64% | 2026-06-30 |
| 2 | Citadel Advisors LLC Custodian | $15.45M | 21.17% | 2026-06-30 |
| 3 | IMC-Chicago, LLC Custodian | $7.93M | 10.86% | 2026-09-30 |
| 4 | Walleye Capital LLC | $6.42M | 8.79% | 2026-06-30 |
| 5 | D. E. Shaw & Co., Inc. Custodian | $4.41M | 6.05% | 2026-06-30 |
| 6 | Twin Tree Management, LP | $4.23M | 5.79% | 2026-06-30 |
| 7 | Jane Street Group, LLC Custodian | $3.16M | 4.33% | 2026-06-30 |
| 8 | Simplex Trading, LLC Custodian | $905.28K | 1.24% | 2026-09-30 |
| 9 | Castellan Group | $441.60K | 0.60% | 2026-09-30 |
| 10 | GROUP ONE TRADING LLC Custodian | $375.70K | 0.51% | 2026-06-30 |
| 11 | Larson Financial Group LLC | $1.48K | <0.01% | 2026-09-30 |
9 filers$44.72M notional
| # | Filer | Notional Value | % of Total | Period |
|---|---|---|---|---|
| 1 | Susquehanna International Group, LLP Custodian | $19.57M | 43.76% | 2026-06-30 |
| 2 | Twin Tree Management, LP | $7.29M | 16.31% | 2026-06-30 |
| 3 | Citadel Advisors LLC Custodian | $5.43M | 12.15% | 2026-06-30 |
| 4 | Walleye Capital LLC | $4.95M | 11.06% | 2026-06-30 |
| 5 | Trilogy Capital Inc. | $3.31M | 7.41% | 2026-09-30 |
| 6 | IMC-Chicago, LLC Custodian | $1.57M | 3.51% | 2026-09-30 |
| 7 | D. E. Shaw & Co., Inc. Custodian | $1.53M | 3.43% | 2026-06-30 |
| 8 | Simplex Trading, LLC Custodian | $540.96K | 1.21% | 2026-09-30 |
| 9 | GROUP ONE TRADING LLC Custodian | $524.41K | 1.17% | 2026-06-30 |
HALO Insider Trading (Form 4)
Latest: 2026-10-08Form 4 filings — insider beneficial-ownership changes by officers, directors, and 10%+ holders. Filed within 2 business days of transaction.
| Filed | Reporter | Role | Action | Shares | Avg Price | Net $ | Link |
|---|---|---|---|---|---|---|---|
| 2026-10-08 | Bernadette Connaughton | Director | Award (A) | +3,796 | — | EDGAR | |
| 2026-10-08 | Helen Torley | PRESIDENT AND CEO | Mixed Exer +60,000 · Sell −60,000 |
— | $64.29 | -$5.51M | EDGAR |
| 2026-10-02 | Matthew L. Posard | Director | Sell (S) | −5,230 | $108.54 | -$567.7K | EDGAR |
| 2026-10-02 | James M Daly | Director | Award (A) | +1,169 | — | EDGAR | |
| 2026-09-17 | Matthew L. Posard | Director | Sell (S) | −18,996 | $107.74 | -$2.05M | EDGAR |
| 2026-09-11 | Helen Torley | PRESIDENT AND CEO | Mixed Exer +60,000 · Sell −60,000 |
— | $62.84 | -$5.33M | EDGAR |
| 2026-09-02 | Dannielle Appelhans | Director | Award (A) | +1,161 | — | EDGAR | |
| 2026-08-19 | Helen Torley | PRESIDENT AND CEO | Mixed Sell −60,000 · Exer +60,000 |
— | $61.50 | -$5.17M | EDGAR |
| 2026-08-11 | Bernadette Connaughton | Director | Sell (S) | −1,626 | $102.80 | -$167.2K | EDGAR |
| 2026-07-09 | Helen Torley | PRESIDENT AND CEO | Mixed Sell −1,923 · Exer +1,923 |
— | $45.92 | -$130.2K | EDGAR |
| 2026-07-02 | Bernadette Connaughton | Director | Sell (S) | −1,625 | $76.71 | -$124.7K | EDGAR |
| 2026-07-02 | Darren Snellgrove | SVP, Chief Financial Officer | Grant (A) | +168,986 opt | — | EDGAR | |
| 2026-07-02 | David A Ramsay | EVP, PRESIDENT, DRUG DELIVERY | Mixed Exer +10,000 · Tax −5,408 |
+4,592 | $78.27 | -$423.3K | EDGAR |
| 2014-05-16 | — | — | — | — | EDGAR | ||
| 2014-05-15 | — | — | — | — | EDGAR |
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (described in filing footnote — typically 401(k), trust, inheritance) · W = will/inheritance. Only P / S codes carry directional signal.
HALO Insider Holdings
6 insiders · @ $102.98
Officers, directors, and 10%+ owners who have filed a Form 4 in the past two years, ranked by current disclosed exposure (shares × today's price). Shares are direct + indirect (via trusts / LLCs / spouse). Excludes unvested RSU and option grants — those aren't beneficially owned until vest.
| # | Insider | Role | Shares | Disclosed Exposure | Lifetime OM Net | Filings | Last Filed |
|---|---|---|---|---|---|---|---|
| 1 | Helen Torley | PRESIDENT AND CEO | 782,970 | $80.63M | -$19.48M | 4 | 2026-10-08 |
| 2 | Matthew L. Posard | Director | 53,709 | $5.53M | -$2.61M | 2 | 2026-10-02 |
| 3 | Bernadette Connaughton | Director | 42,294 | $4.36M | -$291.8K | 3 | 2026-10-08 |
| 4 | David A Ramsay | EVP, PRESIDENT, DRUG DELIVERY | 4,592 | $472.9K | $0 | 1 | 2026-07-02 |
| 5 | James M Daly | Director | 1,169 | $120.4K | $0 | 1 | 2026-10-02 |
| 6 | Dannielle Appelhans | Director | 1,161 | $119.6K | $0 | 1 | 2026-09-02 |
Lifetime OM Net = signed sum of open-market buys (P) and sells (S) over their career; excludes grants, tax withholdings, and dispositions to issuer. A large negative number is normal for long-tenured executives — they've sold compensation grants over many years.
HALO Board & Officers
As of SEC filings through Oct 8, 2026Directors 8
- Matthew L. Posard · since Mar 27, 2013
- Helen Torley · since Jan 6, 2014
- Jeffrey William Henderson · since Aug 5, 2015
- Bernadette Connaughton · since Sep 7, 2018
- Barbara Gayle Duncan · since Feb 3, 2023
- Mahesh Krishnan · since Apr 25, 2024
- James Paul Lang · since Dec 4, 2025
- Dannielle Appelhans · since Aug 14, 2026
Officers 4
- Helen Torley · President and CEO · since Jan 6, 2014
- David A Ramsay · Interim CFO · listed since Mar 2026
- Darren Snellgrove · SVP, Chief Financial Officer · since Jun 8, 2026
- Mark Howard Snyder · SVP, Chief Legal Officer · listed since Jun 2024
Changes in the last 10 years (28)
| Aug 14, 2026 | Dannielle Appelhans became a director |
| Jun 30, 2026 | The company announced the departure of Cortney Caudill as SVP, Chief Operating Officer in an SEC filing |
| Jun 8, 2026 | Darren Snellgrove became SVP, Chief Financial Officer |
| Mar 23, 2026 | David A Ramsay listed as Interim CFO (previously VP and Chief Financial Officer) in SEC filings |
| Dec 4, 2025 | James Paul Lang became a director |
| Nov 3, 2025 | The company announced the departure of Nicole LaBrosse as SVP, Chief Financial Officer in an SEC filing |
| Oct 1, 2025 | Cortney Caudill became SVP, Chief Operating Officer |
| Mar 17, 2025 | The company announced the departure of Michael J. LaBarre as SVP, Chief Technical Officer in an SEC filing |
| Feb 11, 2025 | The company announced the departure of Connie Matsui from the board in an SEC filing |
| Jun 14, 2024 | Mark Howard Snyder listed as SVP, Chief Legal Officer (previously SVP, General Counsel) in SEC filings |
| Apr 25, 2024 | Mahesh Krishnan became a director |
| Feb 22, 2023 | The company announced the departure of James M Daly from the board in an SEC filing |
| Feb 3, 2023 | Barbara Gayle Duncan became a director |
| Mar 24, 2022 | Akiko Moni Miyashita became a director |
| Feb 2, 2022 | The company announced the departure of Elaine D Sun as SVP, Chief Financial Officer in an SEC filing |
| Feb 2, 2022 | Nicole LaBrosse became SVP, Chief Financial Officer |
| Jan 3, 2022 | Mark Howard Snyder became SVP, General Counsel |
| Dec 13, 2021 | The company announced the departure of Masaru Matsuda as SVP, General Counsel in an SEC filing |
| Mar 2, 2020 | Elaine D Sun became SVP, Chief Financial Officer |
| Jan 6, 2020 | Michael J. LaBarre listed as SVP, Chief Technical Officer (previously VP, Product Development) in SEC filings |
| Jan 3, 2020 | Masaru Matsuda became SVP, General Counsel |
| May 6, 2019 | Alison A. Armour became SVP, Research & Development |
| Feb 5, 2019 | Harry J Leonhardt listed as SVP, GC (previously SVP, GC and CCO) in SEC filings |
| Sep 10, 2018 | Benjamin Hickey became SVP, Chief Commercial Officer |
| Sep 7, 2018 | Bernadette Connaughton became a director |
| Aug 28, 2018 | Randal J Kirk reported in an SEC filing no longer being a 10% owner |
| Jun 29, 2018 | Randal J Kirk no longer listed as a director in SEC filings |
| May 2, 2018 | Dimitrios Chondros became SVP, Chief Medical Officer |
Not reported recently (10)
- Akiko Moni Miyashita · Last reported as a director in an SEC filing dated May 2, 2025
- Jean-Pierre Bizzari · Last reported as a director in an SEC filing dated May 9, 2023
- Kenneth J Kelley · Last reported as a director in an SEC filing dated Apr 14, 2021
- Laurie Stelzer · Last reported as SVP, Chief Financial Officer in an SEC filing dated Feb 24, 2020
- Benjamin Hickey · Last reported as SVP, Chief Commercial Officer in an SEC filing dated Oct 1, 2019
- Dimitrios Chondros · Last reported as SVP, Chief Medical Officer in an SEC filing dated Aug 5, 2019
- Alison A. Armour · Last reported as SVP, Research & Development in an SEC filing dated Jun 4, 2019
- Harry J Leonhardt · Last reported as SVP, GC in an SEC filing dated Apr 15, 2019
- Athena Countouriotis · Last reported as SVP and Chief Medical Officer in an SEC filing dated Feb 24, 2017
- Mark J Gergen · Last reported as SVP, Chief Operating Officer in an SEC filing dated Feb 24, 2017
Compiled from SEC filings by the company and its directors and officers. Dates are as stated in those filings. Where no filing says when someone left, we show the last filing that listed them.
HALO Proposed Insider Sales (Form 144)
Latest: 2026-09-16
? Form 144 Guide
Last 30d:
0 filings
· Last 90d:
4 filings
· $31.8M notice value
· 4 unique filers
· 75% under 10b5-1 plans
What is Form 144? A notice of intent to sell restricted or control stock under Rule 144. Affiliates (officers, directors, 10%+ owners) and holders of restricted shares must file Form 144 when planning to sell more than 5,000 shares or $50,000 in any 3-month rolling window.
How it relates to Form 4: Form 144 is filed before the trade (up to 90 days in advance); Form 4 is filed within 2 business days after the trade executes. Not every Form 144 results in a sale — the filer may cancel or delay. Look for the corresponding Form 4 on the Insider Activity card to confirm a sale actually happened.
10b5-1 plans: Trades made under a pre-scheduled Rule 10b5-1 plan are not discretionary — they execute automatically on dates set months earlier, regardless of news. High 10b5-1 percentages mean less per-filing signal value, though cumulative selling volume still matters.
"Notice value": Aggregate market value the filer wrote into the Form 144 — i.e. the size of the planned sale, not necessarily the executed dollars. An amended notice (Form 144/A) replaces the original it amends, and cancelled notices are dropped, so neither is double-counted above. A filed value that is clearly inconsistent with the share count at the stock's price (a filer typo) shows as a dash and is left out of the totals.
Source & freshness: Sourced from public Form 144 filings. Refreshed daily; new filings typically appear here the morning after they are filed.
Top 90-day filers:
Helen Torley (1, $23.7M) · CORTNEY A CAUDILL (1, $4.3M) · MATTHEW POSARD (1, $3.6M) · BERNADETTE CONNAUGHTON (1, $168K)
| Filed | Filer | Role | Shares | Notice Value | Planned Sale | Broker | Plan | Link |
|---|---|---|---|---|---|---|---|---|
| 2026-09-16 | MATTHEW POSARD | Director | 34,226 | $3.64M | 2026-09-16 | Morgan Stanley Smith Barney LLC … | 10b5-1 | EDGAR |
| 2026-08-17 | Helen Torley | President, CEO, Director | 240,000 | $23.68M | 2026-08-17 | J.P. Morgan Securities LLC | 10b5-1 | EDGAR |
| 2026-08-11 | CORTNEY A CAUDILL | Officer | 41,702 | $4.30M | 2026-08-11 | Morgan Stanley Smith Barney LLC … | — | EDGAR |
| 2026-08-10 | BERNADETTE CONNAUGHTON | Director | 1,626 | $167.7K | 2026-08-10 | Morgan Stanley Smith Barney LLC … | 10b5-1 | EDGAR |
| 2026-06-29 | MAHESH KRISHNAN | Director | 7,304 | $547.5K | 2026-06-29 | Morgan Stanley Smith Barney LLC … | 10b5-1 | EDGAR |
| 2026-05-15 | NICOLE LABROSSE | Former Officer | 14,700 | $986.6K | 2026-05-15 | Morgan Stanley Smith Barney LLC … | — | EDGAR |
| 2026-05-11 | Helen Torley | President, CEO, Director | 101,923 | $6.54M | 2026-05-11 | J.P. Morgan Securities LLC | 10b5-1 | EDGAR |
| 2026-05-01 | BERNADETTE CONNAUGHTON | Director | 4,875 | $310.3K | 2026-05-01 | Morgan Stanley Smith Barney LLC … | 10b5-1 | EDGAR |
| 2026-03-10 | CORTNEY A CAUDILL | Officer | 8,857 | $599.1K | 2026-03-10 | Morgan Stanley Smith Barney LLC … | — | EDGAR |
| 2026-03-09 | CORTNEY A CAUDILL | Officer | 20,000 | $1.36M | 2026-03-09 | Morgan Stanley Smith Barney LLC … | — | EDGAR |
Notice value is the aggregate market value the filer states they intend to sell — not a confirmed transaction. Compare to Insider Activity (Form 4) to see which planned sales actually executed. Market-wide feed: Planned sales (Form 144).
Recent SEC Filings
Latest: 2026-11-05
Current reports — material events the company must disclose within 4 business days (earnings releases, M&A, executive changes, etc.).
| Filing Date | Event | Link |
|---|---|---|
| 2026-11-05 | Earnings results | EDGAR |
| 2026-09-30 | Director or officer change | EDGAR |
| 2026-09-22 | Material agreement · New debt obligation · Unregistered share sale | EDGAR |
| 2026-09-18 | Other events | EDGAR |
| 2026-09-16 | Other events | EDGAR |
| 2026-08-18 | Director or officer change | EDGAR |
| 2026-08-06 | Earnings results | EDGAR |
| 2026-07-02 | Director or officer change | EDGAR |
| 2026-05-11 | Earnings results | EDGAR |
| 2026-05-07 | Shareholder vote results | EDGAR |
Annual report — audited financial statements, MD&A, risk factors. Filed 60–90 days after fiscal year-end.
| Filing Date | Accession | Link |
|---|---|---|
| 2026-02-17 | 0001159036-26-000024 | EDGAR |
| 2025-02-18 | 0001159036-25-000010 | EDGAR |
| 2024-02-20 | 0001159036-24-000008 | EDGAR |
| 2023-02-21 | 0001159036-23-000012 | EDGAR |
| 2022-02-22 | 0001159036-22-000014 | EDGAR |
| 2021-02-23 | 0001159036-21-000014 | EDGAR |
| 2020-02-24 | 0001159036-20-000013 | EDGAR |
| 2019-02-21 | 0001159036-19-000006 | EDGAR |
| 2018-02-20 | 0001159036-18-000011 | EDGAR |
| 2017-02-28 | 0001159036-17-000014 | EDGAR |
Quarterly report — unaudited financials and MD&A. Filed 40–45 days after each of the first three fiscal quarters.
| Filing Date | Accession | Link |
|---|---|---|
| 2026-11-05 | 0001159036-26-000145 | EDGAR |
| 2026-08-06 | 0001159036-26-000104 | EDGAR |
| 2026-05-11 | 0001159036-26-000068 | EDGAR |
| 2025-11-03 | 0001159036-25-000045 | EDGAR |
| 2025-08-05 | 0001159036-25-000034 | EDGAR |
| 2025-05-06 | 0001159036-25-000026 | EDGAR |
| 2024-10-31 | 0001159036-24-000050 | EDGAR |
| 2024-08-06 | 0001159036-24-000044 | EDGAR |
| 2024-05-07 | 0001159036-24-000037 | EDGAR |
| 2023-11-06 | 0001159036-23-000057 | EDGAR |
ETF Holders
184 ETFs hold HALO
25 shown · $2.47B total exposure · 0.27% AUM-weighted avg weight
| # | ETF | Provider | Weight | $ Exposure | ETF AUM | As Of |
|---|---|---|---|---|---|---|
| 1 | IJH iShares Core S&P Mid-Cap ETF | iShares (BlackRock) | 0.34% | $421.8M | $124.5B | 2026-11-09 |
| 2 | VTI Vanguard Morningstar Total Stock Market ETF | Vanguard | 0.02% | $397.9M | — | 2026-09-30 |
| 3 | VB Vanguard Morningstar Small-Cap ETF | Vanguard | 0.16% | $282.1M | — | 2026-09-30 |
| 4 | VBK Vanguard Morningstar Small-Cap Growth ETF | Vanguard | 0.36% | $156.9M | — | 2026-09-30 |
| 5 | XBI State Street® SPDR® S&P® Biotech ETF | SPDR (State Street) | 1.38% | $145.7M | $10.5B | 2026-11-09 |
| 6 | VXF Vanguard Extended Market ETF | Vanguard | 0.15% | $141.0M | — | 2026-09-30 |
| 7 | FBT First Trust NYSE® Arca® Biotechnology Index Fund | First Trust | 3.02% | $92.1M | $3.0B | 2026-11-09 |
| 8 | IBB iShares Biotechnology ETF | iShares (BlackRock) | 0.78% | $89.1M | $11.3B | 2026-11-09 |
| 9 | MDY State Street® SPDR® S&P MIDCAP 400® ETF Trust | SPDR (State Street) | 0.34% | $88.4M | $26.4B | 2026-11-09 |
| 10 | IJK iShares S&P Mid-Cap 400 Growth ETF | iShares (BlackRock) | 0.68% | $71.2M | $10.5B | 2026-11-09 |
| 11 | IWP iShares Russell Mid-Cap Growth ETF | iShares (BlackRock) | 0.38% | $68.2M | $18.1B | 2026-11-09 |
| 12 | DFAS Dimensional US Small Cap ETF | Dimensional | 0.19% | $65.8M | — | 2026-11-09 |
| 13 | SPMD State Street® SPDR® Portfolio S&P 400™ Mid Cap ETF | SPDR (State Street) | 0.34% | $64.0M | $19.0B | 2026-11-09 |
| 14 | SCHA Schwab U.S. Small-Cap ETF | Nport | 0.27% | $60.1M | — | 2026-08-31 |
| 15 | IWR iShares Russell Mid-Cap ETF | iShares (BlackRock) | 0.09% | $51.9M | $58.7B | 2026-11-09 |
| 16 | IWF iShares Russell 1000 Growth ETF | iShares (BlackRock) | 0.04% | $45.7M | $117.1B | 2026-11-09 |
| 17 | VHT Vanguard Health Care ETF | Vanguard | 0.18% | $40.0M | — | 2026-09-30 |
| 18 | DFAC Dimensional US Core Equity 2 ETF | Dimensional | 0.04% | $36.5M | — | 2026-11-09 |
| 19 | SCHM Schwab U.S. Mid-Cap ETF | Nport | 0.24% | $34.9M | — | 2026-08-31 |
| 20 | FXH First Trust Health Care AlphaDEX® Fund | First Trust | 2.08% | $24.8M | $1.2B | 2026-11-09 |
| 21 | VONG Vanguard Russell 1000 Growth ETF | Vanguard | 0.04% | $21.2M | — | 2026-09-30 |
| 22 | IVOO Vanguard S&P Mid-Cap 400 ETF | Vanguard | 0.37% | $21.0M | — | 2026-09-30 |
| 23 | MDYG State Street® SPDR® S&P 400™ Mid Cap Growth ETF | SPDR (State Street) | 0.68% | $19.3M | $2.8B | 2026-11-09 |
| 24 | DYNF iShares U.S. Equity Factor Rotation Active ETF | iShares (BlackRock) | 0.04% | $17.6M | $41.6B | 2026-11-09 |
| 25 | SMLF iShares U.S. Small-Cap Equity Factor ETF | iShares (BlackRock) | 0.41% | $17.4M | $4.3B | 2026-11-09 |
Fundamentals
Quarterly filings sourced from SEC 10-Q / 10-K reports. TTM tiles aggregate the most recent four quarters; bars show the last ~12 quarters oldest → newest.
Metrics
- Revenue — top-line sales. Look for consistent YoY growth; seasonal businesses need same-quarter comparisons (Q4 '24 vs Q4 '23).
- Net Income — bottom-line profit after all expenses. Can be volatile from one-time items; red bars = net loss.
- Diluted EPS — net income per share assuming options/converts are exercised. Direct input to the P/E ratio.
- Operating Cash Flow — cash generated from core operations, before capex and financing. Harder to manipulate than net income; growing OCF is a quality signal.
How to read the bars
- Sequential growth — quarter-over-quarter trend. Accelerating bars are a momentum signal.
- YoY growth — compare to the same quarter a year earlier to remove seasonality.
- Quality — OCF should roughly track Net Income over time. Large divergence (net income ≫ OCF) flags accruals risk.
- Margins — scan the bar ratios: Net Income / Revenue tells you margin trend without needing a separate chart.
TTM (trailing-twelve-month) smooths seasonality and is used for the P/E calculation. Filings appear 30–90 days after the period closes.
Trailing P/E
—
TTM Diluted EPS
$3.43
TTM Revenue
$1.66B
TTM Net Income
$413.60M
TTM Op. Cash Flow
$818.60M
Quarterly figures (12 quarters)
| Quarter | Period End | Revenue | Net Income | Diluted EPS | Op. Cash Flow |
|---|---|---|---|---|---|
| Q2 '26 | 2026-06-30 | $481.00M | $229.91M | $1.90 | $240.89M |
| Q1 '26 | 2026-03-31 | $376.71M | $150.05M | $1.22 | $180.08M |
| Q4 '25 | 2025-12-31 | $451.77M | $-141.59M | $-1.12 | $219.03M |
| Q3 '25 | 2025-09-30 | $354.26M | $175.22M | $1.43 | $178.60M |
| Q2 '25 | 2025-06-30 | $325.72M | $165.16M | $1.33 | $99.71M |
| Q1 '25 | 2025-03-31 | $264.86M | $118.09M | $0.93 | $154.22M |
| Q4 '24 | 2024-12-31 | $298.01M | $137.01M | $1.06 | $178.47M |
| Q3 '24 | 2024-09-30 | $290.08M | $137.01M | $1.05 | $115.38M |
| Q2 '24 | 2024-06-30 | $231.35M | $93.25M | $0.72 | $55.79M |
| Q1 '24 | 2024-03-31 | $195.88M | $76.82M | $0.60 | $129.43M |
| Q4 '23 | 2023-12-31 | $230.04M | $85.39M | $0.65 | $102.35M |
| Q3 '23 | 2023-09-30 | $216.03M | $81.84M | $0.61 | $132.41M |
Q2 2026 • period ending 2026-06-30 • filed 2026-08-06
Valuation
Ratios derived from TTM financials and the current market price, sampled daily. History chart shows how expensive the stock is today relative to its own recent past.
Price Multiples
- P/E — price / TTM earnings. Rough market rule: 10–15 value, 15–25 market, >30 growth/premium. Negative when earnings are negative.
- P/B — price / book value. Useful for financials and asset-heavy names; meaningless for asset-light software.
- P/S — price / TTM revenue. Useful when earnings are negative or noisy (early-stage growth).
- EV/EBITDA — capital-structure-neutral. <10 cheap, 10–15 reasonable, >20 rich. Good for comparing across leverage profiles.
- EV/Sales — like P/S but accounts for debt + cash. Compare within sector.
Profitability & Yields
- ROE — return on equity. >15% strong, >25% exceptional. Caution: high leverage inflates ROE.
- ROA — return on assets. Leverage-neutral; >5% solid, >10% exceptional.
- Div Yield — annual dividend / price. Compare to 10Y Treasury; sustained yield >6% often signals distress.
- FCF Yield — free cash flow / market cap. >5% is attractive; negative means burning cash.
Balance Sheet
- Debt/Equity — leverage. <1 conservative, >2 aggressive. Sector-dependent (utilities naturally high, tech low).
- Current Ratio — short-term liquidity. >1.5 comfortable, <1 raises short-term solvency flags.
Reading the history chart
- Compare current level to the 3-year band: near the high end = relatively expensive; near the low = relatively cheap.
- Multiples expanding while earnings are flat = sentiment-driven rally.
- Multiples compressing while earnings grow = value coming from fundamentals.
P/E
30.02
P/B
87.94
P/S
7.59
EV/EBITDA
13.77
EV/Sales
8.65
ROE
288.1%
ROA
16.0%
Div Yield
0.00%
FCF Yield
6.48%
Debt/Equity
13.50
Current Ratio
—
Market Cap
$12.62B
as of 2026-11-10
HALO vs Peers
Related companies, largest first| Company | Market cap | P/E | Revenue growth | YTD | IV rank |
|---|---|---|---|---|---|
| AMGN Amgen Inc | $251.6B | 27.0 | +8.2% | +42.0% | 36 |
| GILD Gilead Sciences Inc | $210.0B | — | +6.5% | +40.5% | 43 |
| VRTX Vertex Pharmaceuticals Inc | $139.7B | 35.3 | +10.5% | +21.2% | 60 |
| REGN Regeneron Pharmaceuticals Inc | $95.2B | 20.2 | +18.6% | +18.0% | 54 |
| BIIB Biogen Inc. Common Stock | $37.7B | 108.2 | +2.3% | +42.4% | 97 |
| UTHR United Therapeutics Corp | $24.8B | 22.2 | +1.9% | +18.5% | 22 |
| EXEL Exelixis Inc | $17.5B | 21.1 | +9.1% | +62.0% | 19 |
| NBIX Neurocrine Biosciences Inc | $17.1B | 25.1 | +38.0% | +20.3% | 24 |
| HALO Halozyme Therapeutics, Inc. | $11.7B | 30.0 | +41.2% | +46.5% | 49 |
| Peer median | $66.4B | 25.1 | +8.6% | +30.8% | 39 |
P/E uses the latest reported trailing-12-month diluted EPS; "—" means no positive earnings or no data.
Short Interest & Float
Regulatory short-interest reports publish on a bi-weekly settlement cadence; short-volume is reported daily by the trade-reporting facilities. Float is derived from insider-ownership filings.
Metric definitions
- Short Interest — total shares currently sold short as of the settlement date. Lags real time by ~8 business days.
- SI % of Float — short interest / free float. The key crowding metric.
- Days to Cover — short interest / avg daily volume. How many full trading days it would take shorts to buy back. High DTC + catalyst = squeeze fuel.
- Short Vol Ratio — today's short-sale volume / total volume. Intraday selling pressure proxy (not the same as short interest).
- Free Float — shares available for public trading (total shares minus insider / restricted).
- Float % — free float / shares outstanding. <50% = tightly held, more prone to squeezes.
How to read the signals
- SI % of Float < 5% — typical, no particular signal.
- 5–15% — elevated; watch for catalysts (earnings, guidance, macro).
- 15–30% — heavily shorted; tight-float names in this range have produced notable squeezes historically.
- >30% — extreme; borrow is likely expensive and squeeze risk is material.
- Days to Cover > 5 combined with high SI% amplifies squeeze potential.
History chart
- Trend matters more than level. Rapidly rising short interest often precedes negative catalysts or heavy hedging.
- A sudden drop in SI after a rally may indicate a squeeze in progress.
Short interest is reported mid-month and end-of-month; short volume is daily.
Short Interest
13.65M
SI % of Float
12.36%
Days to Cover
6.16
Short Vol Ratio
63.3%
Free Float
110.43M
Float %
97.3%
Short interest 2026-10-15 • Short volume 2026-11-10 • Float 2026-08-07